Industry news

Survey Results Explores Biopharma Risk Model

BioPharm International

Biopharmaceutical executives are optimistic about their abilities to launch new drugs, in the next five years, but nearly one-third voiced concerns about potential regulatory roadblocks, according to a survey sponsored by MilliporeSigma and conducted by the Economist Intelligence Unit. The survey results were released at the 2016 BIO International Convention in San Francisco in early June 2016.

Cancer data collections efforts grow in China

EJ Lane / Fierce Pharma

Two examples of efforts to expand data insights into cancer in China show the potential scope of a national "big data plan" for healthcare for both domestic and foreign players outlined in June--a policy that seeks to standardize patient and clinical data on a massive scale by the end of the decade.

Ferring announces data from its Phase III ESTHER trials

Victoria White / European Pharmaceutical Review

Ferring Pharmaceuticals have announced data from their ESTHER trials at the Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE).

International collaboration to create new cancer models to accelerate research

U.S. National Institute od Health

An international project to develop a large, globally accessible bank of new cancer cell culture models for the research community launched today. The National Cancer Institute (NCI), part of the National Institutes of Health; Cancer Research UK, London; the Wellcome Trust Sanger Institute, Cambridge, England; and the foundation Hubrecht Organoid Technology, Utrecht, Netherlands, are joining forces to develop the Human Cancer Models Initiative (HCMI), which will bring together expertise from around the world to make about 1,000 cancer cell models.

Diabetes sales rocket toward $60B

Tracy Staton / Fierce Biotech

Two sides of one coin will keep diabetes drug sales growing--big time--through 2025. The disease is growing fast around the world, and treatment arbiters advise a more aggressive approach to blood-sugar control.

Can healthcare advertising break onto the Cannes ad festival main stage?

Beth Snyder Bulik / FiercePharmaMarketing

Rumblings from healthcare agency executives and marketers about the separation of the Lions Health Festival from the full Cannes Lions International Festival of Creativity were reported inAdvertising Age's final analysis of the event. It noted the "grousing by agency, client and media executives alike" and named WebMD CEO David Schlanger as one of the executives who "believes it's time to more fully integrate health into the main show."

Business as usual for now, but post-Brexit funding, R&D worries remain at forefront

Nuala Moran / BiWorld

One week on, and researchers in the U.K. still reeling from the Brexit vote have been told by the science minister Jo Johnson to carry on as before. In legal terms, nothing has changed. "We remain an EU member during the two-year negotiation period, with all rights and obligations that derive from this," Johnson said in a speech given at the headquarters of research charity the Wellcome Trust, to an audience including university vice chancellors, representatives of research funding bodies and practicing scientists.

Where should the EMA move to? That’s not up to us, regulator says

Ben Adams / Fierce Biotech

Confidentially, EMA head Guido Rasi has said that a move from the U.K. to leave the EU was “a nightmare with immediate consequences,” although publicly the regulator has been keen to dampen concerns from behind a wall of silence.

Transparency is the goal as Europe goes live on payment disclosure

Nuala Moran / BiWorld

Websites publishing details of payments from pharma companies to health care professionals have gone live as Europe presses the button on its version of the U.S. Sunshine Act, and makes information on money paid to individuals available for public scrutiny for the first time.

Medical school hasn’t changed much in a century. Here are 5 ways to fix that

Akhilesh Pathipati / STAT

Like many aspects of health care, medical education evolves slowly. The modern curriculum is based on the Flexner Report — a review published in 1910. It hasn’t changed much since then.